Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.
Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...
Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...
Samsung’s ADC segregated suite, equipped with a 500-liter reactor, supports the development and manufacture of ADC therapies.